
BioHarvest Sciences (BHST) Stock Forecast & Price Target
BioHarvest Sciences (BHST) Analyst Ratings
Bulls say
BioHarvest Sciences Inc demonstrated significant financial growth, achieving record revenues of $6.5 million in the third quarter of 2024, which represents a substantial year-over-year increase of 102%. The company’s robust performance is largely attributed to its flagship nutraceutical product VINIA, highlighting the strong market demand for its innovative health and wellness offerings. Furthermore, favorable market trends in both the pharmaceutical and cosmetics contract development and manufacturing organization (CDMO) sectors, which are projected to experience considerable growth in the coming years, position BioHarvest’s proprietary botanical synthesis technology favorably within these expanding markets.
Bears say
BioHarvest Sciences Inc. faces significant operational risks stemming from potential difficulties in retaining or replacing key management personnel, which could compromise the company’s efficiency and growth potential. Additionally, the company's reliance on consumer acceptance of new products and its ability to secure contractual agreements with Contract Development and Manufacturing Organizations (CDMOs) raises concerns about revenue generation amidst competitive pressures. Furthermore, challenges in maintaining its intellectual property protections and quality management processes could exacerbate financial vulnerabilities, contributing to a pessimistic outlook regarding its market position and overall financial performance.
This aggregate rating is based on analysts' research of BioHarvest Sciences and is not a guaranteed prediction by Public.com or investment advice.
BioHarvest Sciences (BHST) Analyst Forecast & Price Prediction
Start investing in BioHarvest Sciences (BHST)
Order type
Buy in
Order amount
Est. shares
0 shares